191 related articles for article (PubMed ID: 28779004)
1. Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry.
Goldberg M; Bell K; Aronson M; Semotiuk K; Pond G; Gallinger S; Zbuk K
J Med Genet; 2017 Nov; 54(11):742-746. PubMed ID: 28779004
[TBL] [Abstract][Full Text] [Related]
2. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
3. Evidence for breast cancer as an integral part of Lynch syndrome.
Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
[TBL] [Abstract][Full Text] [Related]
4. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
[TBL] [Abstract][Full Text] [Related]
6. A population-based study of hereditary non-polyposis colorectal cancer: evidence of pathologic and genetic heterogeneity.
Warden G; Harnett D; Green J; Wish T; Woods MO; Green R; Dicks E; Rahman P; Zhai G; Parfrey P
Clin Genet; 2013 Dec; 84(6):522-30. PubMed ID: 23278430
[TBL] [Abstract][Full Text] [Related]
7. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study.
Harkness EF; Barrow E; Newton K; Green K; Clancy T; Lalloo F; Hill J; Evans DG
J Med Genet; 2015 Aug; 52(8):553-6. PubMed ID: 26101330
[TBL] [Abstract][Full Text] [Related]
8. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
[TBL] [Abstract][Full Text] [Related]
9. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT
J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries.
Ryan P; Mulligan AM; Aronson M; Ferguson SE; Bapat B; Semotiuk K; Holter S; Kwon J; Kalloger SE; Gilks CB; Gallinger S; Pollett A; Clarke BA
Cancer; 2012 Feb; 118(3):681-8. PubMed ID: 21721000
[TBL] [Abstract][Full Text] [Related]
11. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.
Boilesen AE; Bisgaard ML; Bernstein I
Acta Obstet Gynecol Scand; 2008; 87(11):1129-35. PubMed ID: 18972272
[TBL] [Abstract][Full Text] [Related]
12. Risks of less common cancers in proven mutation carriers with lynch syndrome.
Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
[TBL] [Abstract][Full Text] [Related]
13. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.
Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT
Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828
[TBL] [Abstract][Full Text] [Related]
14. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X.
Lindor NM; Rabe K; Petersen GM; Haile R; Casey G; Baron J; Gallinger S; Bapat B; Aronson M; Hopper J; Jass J; LeMarchand L; Grove J; Potter J; Newcomb P; Terdiman JP; Conrad P; Moslein G; Goldberg R; Ziogas A; Anton-Culver H; de Andrade M; Siegmund K; Thibodeau SN; Boardman LA; Seminara D
JAMA; 2005 Apr; 293(16):1979-85. PubMed ID: 15855431
[TBL] [Abstract][Full Text] [Related]
15. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
[TBL] [Abstract][Full Text] [Related]
16. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
[TBL] [Abstract][Full Text] [Related]
18. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
19. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
20. Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X.
Bucksch K; Zachariae S; Ahadova A; Aretz S; Büttner R; Görgens H; Holinski-Feder E; Hüneburg R; Kloor M; von Knebel Doeberitz M; Ladigan-Badura S; Moeslein G; Morak M; Nattermann J; Nguyen HP; Perne C; Redler S; Schmetz A; Steinke-Lange V; Surowy H; Vangala DB; Weitz J; Loeffler M; Engel C;
Int J Cancer; 2022 Jan; 150(1):56-66. PubMed ID: 34469588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
